(1R,2S)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol;hydron;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (1R,2S)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol;hydron;chloride
• 化学式: C16H26ClNO2
• 分子量: 299.83
• InChiKey: PPKXEPBICJTCRU-DMLYUBSXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.06
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  32.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Opioid Detection
  申请人：Randox Laboratories Limited

  公开号：US20170176476A1

  公开（公告）日：2017-06-22

  An immunoassay method is described which detects O-desmethyltramadol only. This enables an assay of high sensitivity and specificity avoiding false positive results. The unique antibodies incorporated in the immunoassay method can be combined with antibodies which detect mitragynine to provide an assay which increases the possibility of detecting the commonly found drug combination of O-desmethyltramadol and mitragynine.

  描述了一种免疫分析方法，仅检测O-去甲基曲马多。这使得检测具有高灵敏度和特异性的方法成为可能，避免了假阳性结果。免疫分析方法中所包含的独特抗体可以与检测米特拉吉宁的抗体结合，从而提供一种增加检测常见药物组合O-去甲基曲马多和米特拉吉宁可能性的检测方法。
• Tramadol recovery process
  申请人：IPCA Laboratories Limited

  公开号：EP1785412A1

  公开（公告）日：2007-05-16

  A process for the resolution of isomeric tramadol mixtures comprising: providing a purification stock comprising both cis and trans tramadol; contacting the purification stock with an acid under conditions effective to form an acid salt of the cis and trans tramadol in the purification stock; and separating the cis tramadol acid salt from the trans tramadol to obtain a purified cis tramadol acid salt; and optionally converting the cis tramadol acid salt to cis tramadol or to a pharmaceutically active salt thereof.

  一种用于分离同分异构的曲马多混合物的方法，包括：提供一个包含顺式和反式曲马多的纯化原料；将该纯化原料与酸接触，在有效条件下形成顺式和反式曲马多的酸盐；将顺式曲马多酸盐与反式曲马多分离，获得纯化的顺式曲马多酸盐；可选择将顺式曲马多酸盐转化为顺式曲马多或其药用活性盐。
• [EN] INDUSTRIAL PROCESS FOR CIS(+M-2-R(DIMETHYLAMINO)-METHYL-1-(3- METHOXYPHENYL) CYCLOHEXANOL HYDROCHLORIDE<br/>[FR] PROCÉDÉ INDUSTRIEL POUR LA PRÉPARATION DE CIS(+M-2-R(DIMÉTHYLAMINO)-MÉTHYL-1-(3- MÉTHOXYPHÉNYL) CYCLOHEXANOL CHLORHYDRATE
  申请人：KAMUD DRUGS PVT LTD

  公开号：WO2010032254A1

  公开（公告）日：2010-03-25

  The present invention provides a process for the preparation of cis(+/-)-2- [(dimethylamino)-methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride using the stable nitrate salt as an intermediate to give a product containing less than 0.2 % of the undesired "Trans" diastereomer.

  本发明提供了一种制备顺式(+/-)-2-[(二甲氨基)甲基]-1-(3-甲氧基苯基)环己醇盐酸盐的方法，其中使用稳定的硝酸盐作为中间体，以得到含有少于0.2％的不良的“反式”对映异构体的产物。
• Compositions for nasal delivery
  申请人：Touitou Elka

  公开号：US20090047234A1

  公开（公告）日：2009-02-19

  The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition comprising a therapeutically effective amount of this agent, phospholipids, one or more C2-C4 alcohols and water, wherein the concentrations of the phospholipids and the one or more alcohols in the composition are in the ranges of 0.2 to 10% and 12 to 30% by weight, respectively, with the water content of said composition being not less than 30% by weight, the phospholipids forming vesicles in said composition. Further are disclosed pharmaceutical compositions and combinations suitable for intranasal delivery.

  本发明涉及一种给需要的患者施用至少一种活性药物的方法，该方法包括经鼻给药一种组合物，该组合物包括治疗有效量的该药物、磷脂、一种或多种C2-C4醇和水，其中该组合物中磷脂和一种或多种醇的浓度分别在0.2%至10%和12%至30%之间，该组合物的水含量不少于30%的重量，磷脂在该组合物中形成泡腔。此外，还公开了适用于经鼻给药的药物组合物和组合。
• ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS AND METHODS FOR REDUCING, PREVENTING OR TREATING PAIN AND INFLAMMATION
  申请人：ZANELLA John

  公开号：US20090263489A1

  公开（公告）日：2009-10-22

  Effective treatments of acute pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulfasalazine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

  提供了治疗急性疼痛和/或炎症的有效方法，可以持续一段时间。通过在目标部位或附近给予足够的磺胺嘧啶，可以缓解由不同来源引起的疼痛，包括但不限于脊椎盘突出（即坐骨神经痛）、脊柱侧弯、狭窄、盘源性背痛和关节疼痛以及手术后的疼痛。当在可生物降解聚合物中提供适当的配方时，这种缓解可以持续至少三天。在某些实施例中，缓解可以持续至少25天、至少50天、至少100天、至少135天或至少180天。